E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Enfermedad Renal Crónica Moderada o Grave |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064848 |
E.1.2 | Term | Chronic kidney disease |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To demonstrate AST-120, added to standard-of-care therapy in moderate to severe CKD, reduces the risk of progression of CKD as assessed by the development of a component of a triple composite endpoint (initiation of dialysis, kidney transplant, or doubling of sCr), when compared with placebo; and • To demonstrate the general safety and tolerability of long-term AST-120 therapy in CKD patients. |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the efficacy of AST-120 in reducing the risk of developing a component of a quadruple composite endpoint (initiation of dialysis, kidney transplant, doubling of sCr, or death) compared with placebo; • To evaluate the effects of AST-120 versus placebo, on other measures of renal function i.e. sCr, 24 hr urinary protein excretion, creatinine clearance, urea clearance, and 24 hr urinary creatinine excretion; and • To assess the effects of AST-120 versus placebo, on fat-soluble vitamin levels (A, D, E, and K), vitamin B-12, and folate levels. Exploratory objective of this study is; • To assess quality of life by KDQOL ™-36 questionnaire.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients that meet all of the following Inclusion Criteria may be enrolled into the study: 1) Age 18 years or older; 2) Moderate to severe CKD (sCr ≥ 2.0 mg/dL[≥ 177 µmol/L] and ≤ 5.0 mg/dL[≤ 442 µmol/L]), not anticipated to require dialysis or renal transplant within the next 6 months; 3) Patient survival expected to be no less than one year; 4) Serum creatinine ≥ 2.0 mg/dL [≥ 177 µmol/L] and ≤ 5.0 mg/dL [≤ 442 µmol/L] at the initial Screening visit; 5) Proteinuria / Progressive deterioration in renal function: Urinary total protein to urinary total creatinine ratio (both values measured as mg/dL, or other like units) must be ≥ 0.5 on a spot void obtained at the Screening visit OR If the urinary total protein to urinary total creatinine ratio is <0.5, then the patient may return for a second Screening visit 3 months later. If the sCr value at the second Screening visit is >10% higher than the first Screening visit but not > 5.0 mg/dL [≤ 442 µmol/L] or if the urinary total protein to urinary total creatinine ratio is ≥ 0.5, then the patient may be enrolled. 6) Sitting blood pressure < 160/90 mmHg at both Screening and Baseline visits. In addition, blood pressure, if measured, must have been stable in hypertensive patients over the 3 months prior to Screening, with no more than 1 blood pressure reading > 160/90 mmHg; 7) In patients being treated for hypertension, they should be on a stable anti-hypertensive regimen, defined as no changes in anti-hypertensive medications or doses in the last 3 months prior to the Baseline visit, and to include a stable dose of either an ACEI or ARB unless contraindicated; 8) Stable nutritional status; and 9) Willingness to comply with the study and sign a written informed consent. |
|
E.4 | Principal exclusion criteria |
Patients that meet any of the following Exclusion Criteria must not be enrolled into the study: 1) Obstructive or reversible cause of kidney disease; 2) Nephrotic syndrome defined as a ratio of urinary total protein to urinary creatinine (both components measured as mg/dL or other like units) of > 6.0 as measured on a spot void; 3) Adult polycystic kidney disease; 4) History of previous kidney transplant; 5) History of alcohol or drug abuse within the past 12 months; 6) Known human immunodeficiency virus (HIV) infection; 7) Received immunosuppressive therapy (including systemic corticosteroids for more than 5 days at a daily dose in excess of 0.1 mg/kg, prednisone equivalent) in the past 3 months, or anticipated to require such treatment during the study course; 8) History of recent (within the past 6 months) accelerated or malignant hypertension; 9) Patients who are likely to require changes in ACEI or ARB regimens during the course of this study; 10) Uncontrolled arrhythmia or severe cardiac disease (New York Heart Association Class III -IV), including myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, cerebrovascular accident, or transient ischemic attack within the past 6 months; 11) History of malabsorption, inflammatory bowel disease, hiatal hernia, active peptic ulcer, or severe GI dysmotility, not attributable to the use of a phosphate binder; 12) History of cancer within the past 5 years (cervical carcinoma in situ, low-grade cutaneous malignancy, or other low grade malignancy are exemptions); 13) Alanine transaminase (ALT) or aspartate transaminase (AST) values > 2.5 times the upper limit of normal (ULN); 14) Received any investigational agent or participated in a clinical study within the previous 3 months; 15) Presence of any significant medical condition that might create an undue risk with study participation, or significantly confound the collection of safety and efficacy data in this study; or 16) For women of childbearing potential, a positive pregnancy test result of serum beta human chorionic gonadotropin (βHCG) or unwillingness to use approved single barrier or oral contraception, or unwillingness to be sexually abstinent. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be the occurrence of one component of a triple composite of renal outcomes: initiation of dialysis, kidney transplantation, or doubling of sCr from the value obtained at the Baseline visit (Visit 2). The initial doubled (from Baseline) sCr result will be verified 5-10 days later with another sCr sampling. If this result remains doubled, a confirmatory measurement of sCr doubling will occur at 4-6 weeks after the initial doubled result was reported. If the Baseline value is not available for comparison, the value obtained at the Screening visit (Visit 1) will be used, If a second screening visit is performed then that screening value will be used. An Endpoint Adjudication Committee (EAC) will review and adjudicate all potential endpoint events.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 22 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
When 291 renal outcome events have occured and met the criteria for an adjudicated study event, the study will be considered completed. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |